New developments in the medical treatment of endometriosis

Emerging medical treatments (gonadotropin-releasing hormone antagonists, selective receptor modulators, aromatase inhibitors, immunomodulators, and antiangiogenic drugs targeting different pathways) will be important for precision health (personalized medicine) in endometriosis.

Like Comment

Volume 107, Issue 3, Pages 555–565

Authors:

Mohamed A. Bedaiwy, M.D., Ph.D., Sukinah Alfaraj, M.D., Paul Yong, M.D., Ph.D., Robert Casper, M.D.

Abstract:

Endometriosis affects 1 in 10 women of reproductive-age. The current treatments are surgical and hormonal but have limitations, including the risk of recurrence, side effects, contraceptive action for women who desire pregnancy, and cost. New treatments include gonadotropin-releasing hormone analogues, selective progesterone (or estrogen) receptor modulators, aromatase inhibitors, immunomodulators, and antiangiogenic agents. Further research is needed into central sensitization, local neurogenesis, and the genetics of endometriosis to identify additional treatment targets. A wider range of medical options allows for the possibility of precision health and a more personalized treatment approach for women with endometriosis.


Read the full text here.

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.

No comments yet.